Molecular mechanisms activating muscle protein degradation in chronic kidney disease and other catabolic conditions.
about
Role of proteasomes in disease.Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.Natural history of skeletal muscle mass changes in chronic kidney disease stage 4 and 5 patients: an observational studyIntrinsic apoptosis in mechanically ventilated human diaphragm: linkage to a novel Fos/FoxO1/Stat3-Bim axis.Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies.Angiotensin II as candidate of cardiac cachexiaSerological muscle loss biomarkers: an overview of current concepts and future possibilitiesDuring muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation.Apoptosis initiation of β-ionone in SGC-7901 gastric carcinoma cancer cells via a PI3K-AKT pathway.Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis.Influence of glutamine infusion on ubiquitin, caspase-3, cathepsins L and B, and m-calpain expression in sheep with nutritionally induced metabolic acidosis.Heightened levels of circulating 20S proteasome in critically ill patients.Protein metabolism in slow- and fast-twitch skeletal muscle during turpentine-induced inflammation.A novel puromycin decorporation method to quantify skeletal muscle protein breakdown: A proof-of-concept study.
P2860
Q33307877-9D7CB9DC-D4B2-43A1-918A-0AFA29377813Q33349016-5B541DCE-378A-4707-A3C9-A0CC323335D8Q34761344-E218B70F-7F90-43E3-AA34-FC03FAE00035Q35169490-23F3C6B8-E825-4B57-BDFE-3162B058F42FQ36202135-717C1F0B-51DE-43DC-937A-B37D8817C79FQ36445136-29F9A71F-81AC-442F-90B5-E9E558337064Q36636397-E2C390F0-850E-4979-B370-FCEECE6AC567Q37264046-29BEB52B-187C-450B-A438-0A536281E396Q39253128-AACD8A5F-5E0B-4504-9B3D-BBB1B218C0E6Q39957963-C577446B-EF85-4E26-AFC8-81841B96D4B1Q45329196-92723251-F641-4403-8B45-A84EEE5E0AC9Q46104663-4C0AE76F-775A-4CF6-9DCC-4CC40FC898A1Q46539143-A9F9AD47-1999-465E-B873-D1A3A4088FAFQ46806367-4DA325AC-345B-4CFB-B96E-9B604986A890Q47114366-201F2183-1986-4EC2-91A0-286DDAB751F4
P2860
Molecular mechanisms activating muscle protein degradation in chronic kidney disease and other catabolic conditions.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Molecular mechanisms activatin ...... nd other catabolic conditions.
@ast
Molecular mechanisms activatin ...... nd other catabolic conditions.
@en
Molecular mechanisms activatin ...... nd other catabolic conditions.
@nl
type
label
Molecular mechanisms activatin ...... nd other catabolic conditions.
@ast
Molecular mechanisms activatin ...... nd other catabolic conditions.
@en
Molecular mechanisms activatin ...... nd other catabolic conditions.
@nl
prefLabel
Molecular mechanisms activatin ...... nd other catabolic conditions.
@ast
Molecular mechanisms activatin ...... nd other catabolic conditions.
@en
Molecular mechanisms activatin ...... nd other catabolic conditions.
@nl
P2093
P2860
P1476
Molecular mechanisms activatin ...... nd other catabolic conditions.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2362.2005.01473.X
P577
2005-03-01T00:00:00Z